Stocks:
5,169
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.09T
24h Vol:
$8.59B
Dominance:
MSFT:4.90%
Stocklytics Platform
Asset logo for symbol NVAX
Novavax
NVAX
67
$14.40arrow_drop_down4.31%-$0.65

Performance History

Chart placeholder
Key Stats
Open$14.32
Prev. Close$15.05
EPS-3.05
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$2.22B
PE Ratio-
LOWHIGH
Day Range13.50
14.89
52 Week Range3.53
23.86
Ratios
P/B Ratio49.52
Revenue$983.70M
Operating M. %-147.81%
Earnings$0.00
Earnings Growth %17.16%
EBITDA Margin %-33.94%
ROE %-898.20%
EPS-3.05

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

info
There's no data available for Analyst Forecast

Analyst Ratings

info
There's no data available for Analyst Ratings

Correlated Companies

PRICE$878.45
24H (%)arrow_drop_down0.55%
24H ($)-$4.88
MARKET CAP$771.28B
PRICE$497.12
24H (%)arrow_drop_down0.03%
24H ($)-$0.17
MARKET CAP$443.63B
PRICE$145.53
24H (%)arrow_drop_up0.06%
24H ($)$0.09
MARKET CAP$347.62B
PRICE$129.48
24H (%)arrow_drop_up0.08%
24H ($)$0.11
MARKET CAP$318.88B

About Novavax (NVAX)

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. John Charles Jacobs M.B.A.
Headquarters
Gaithersburg
Employees
1992
Exchange
NASDAQ
add Novavax  to watchlist

Keep an eye on Novavax

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Novavax 's (NVAX) price per share?

The current price per share for Novavax (NVAX) is $14.4. The stock has seen a price change of -$0.65 recently, indicating a -4.32% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Novavax (NVAX)?

For Novavax (NVAX), the 52-week high is $23.86, which is 65.69% from the current price. The 52-week low is $3.53, the current price is 307.93% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Novavax (NVAX) a growth stock?

Novavax (NVAX) has shown an average price growth of 0.41% over the past three years. It has received a score of -1 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Novavax as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Novavax (NVAX) stock price performance year to date (YTD)?

As of the latest data, Novavax (NVAX) has a year-to-date price change of 186.28%. Over the past month, the stock has experienced a price change of 11.63%. Over the last three months, the change has been 172.21%. Over the past six months, the figure is 166.67%. Looking at a longer horizon, the five-year price change stands at 182.35%.

help
Is Novavax (NVAX) a profitable company?

Novavax (NVAX) has a net income of -$545.06M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 71.59% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -147.81% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $983.7M, although specific revenue growth data is currently not available. The gross profit is $704.24M. Operating income is noted at -$415.03M. Furthermore, the EBITDA is -$333.84M.

help
What is the market capitalization of Novavax (NVAX)?

Novavax (NVAX) has a market capitalization of $2.23B. The average daily trading volume is 22.07M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level